Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) will be posting its quarterly earnings results before the market opens on Monday, November 6th. Analysts expect Bellerophon Therapeutics to post earnings of ($0.19) per share for the quarter.
Bellerophon Therapeutics (NASDAQ:BLPH) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.03. On average, analysts expect Bellerophon Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Bellerophon Therapeutics, Inc. (BLPH) opened at $1.40 on Friday.
BLPH has been the topic of a number of recent research reports. Zacks Investment Research raised shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a report on Tuesday, July 11th. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Bellerophon Therapeutics in a report on Wednesday, September 6th. Finally, ValuEngine raised shares of Bellerophon Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 8th.
COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.com-unik.info/2017/11/04/bellerophon-therapeutics-inc-blph-set-to-announce-earnings-on-monday.html.
A hedge fund recently raised its stake in Bellerophon Therapeutics stock. Vanguard Group Inc. raised its position in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) by 52.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 612,641 shares of the biotechnology company’s stock after purchasing an additional 211,111 shares during the quarter. Vanguard Group Inc. owned about 1.86% of Bellerophon Therapeutics worth $821,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 45.86% of the company’s stock.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
What are top analysts saying about Bellerophon Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bellerophon Therapeutics Inc. and related companies.